This is an important finding underlying the need of performing PSMA-PET/CT at early BCR stages where the probability of finding limited disease spread (OMD) is higher, leading to increased treatment efficacy and better outcomes. The gene discussed is FOLH1; the disease is occult macular dystrophy.